McCall W V
Department of Psychiatry and Behavioral Medicine, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA.
J Clin Psychiatry. 2001;62 Suppl 10:27-32.
Insomnia is a cardinal symptom for many psychiatric disorders, especially depressive disorders. Treatment of the underlying psychiatric disorder may be sufficient to relieve the accompanying insomnia. If the insomnia fails to respond, then consideration should be given to the possibility of inadequate treatment of the primary psychiatric disorder, iatrogenic insomnia, insomnia related to a medical disorder, or learned/habit insomnia. Persistent insomnia should be aggressively pursued, since it has been associated with a variety of adverse outcomes in samples of depressed patients. The physician should always inquire about and encourage healthy sleeping behaviors, even if hypnotic medication is contemplated. Benzodiazepines and nonbenzodiazepine benzodiazepine receptor agonists (BzRAs) have the best evidence for efficacy as hypnotics, although sedating antidepressants are popularly prescribed. Although all benzodiazepine hypnotics and nonbenzodiazepine BzRAs are comparably efficacious in inducing sleep, they vary markedly in their potential for residual side effects.
失眠是许多精神疾病尤其是抑郁症的主要症状。治疗潜在的精神疾病可能足以缓解伴随的失眠。如果失眠没有得到改善,则应考虑原发性精神疾病治疗不足、医源性失眠、与躯体疾病相关的失眠或习得性/习惯性失眠的可能性。应积极治疗持续性失眠,因为在抑郁症患者样本中,它与多种不良后果相关。即使考虑使用催眠药物,医生也应始终询问并鼓励健康的睡眠行为。苯二氮䓬类药物和非苯二氮䓬类苯二氮䓬受体激动剂(BzRAs)作为催眠药的疗效证据最为充分,尽管镇静性抗抑郁药也被广泛使用。虽然所有苯二氮䓬类催眠药和非苯二氮䓬类BzRAs在诱导睡眠方面疗效相当,但它们在残留副作用的可能性上有显著差异。